NCT07816575Completed
Comparative Efficacy of Alpha Hydroxy Acids With and Without Nanocarriers Versus Calcipotriol Plus Betamethasone in Treatment of Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
The aim of this double blind comparative clinical study is to evaluate the efficacy of AHAs combined with nanocarriers and their use as a non steroidal alternative drug for long term management of plaque psoriasis
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 8 Sept 2026
- Start date
- 15 Mar 2024
- Primary completion date
- 3 Jul 2025
- Lead sponsor
- Al-Azhar University
- Diseases
- Psoriasis
- NCT number
- NCT07816575
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 15 Mar 2024 to the primary completion date, 3 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with acute renal insufficiency.
Other
- Severe irritation and highly inflamed skin.
- Pregnant and lactating females.
- Face, flexural and groin lesions.
Who the study is looking for
- Age from18-65 years old.
- Denovo psoriatic patients and patients with no psoriasis therapy in the previous two months.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Al-Hussien and cairo dermatology Hospital Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.